JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Establishment Labs (NASDAQ:ESTA) Stock

Establishment Labs (NASDAQ:ESTA) had its price target increased by JPMorgan Chase & Co. from $84.00 to $95.00 in a report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 19.72% from the company’s current price.

ESTA has been the topic of several other reports. Citigroup increased their price target on shares of Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research report on Thursday. BTIG Research increased their target price on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday. Needham & Company LLC lifted their price target on Establishment Labs from $86.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday. Finally, TD Cowen boosted their target price on shares of Establishment Labs from $95.00 to $117.00 and gave the company a “buy” rating in a research report on Monday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $100.25.

Establishment Labs Stock Performance

ESTA stock traded up $0.30 during midday trading on Friday, reaching $79.35. 283,373 shares of the company were exchanged, compared to its average volume of 552,277. Establishment Labs has a one year low of $33.35 and a one year high of $97.59. The firm has a market capitalization of $2.34 billion, a price-to-earnings ratio of -53.29 and a beta of 1.07. The business has a 50-day moving average price of $86.29 and a two-hundred day moving average price of $74.23. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to the consensus estimate of $65.79 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. Establishment Labs’s revenue for the quarter was up 31.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.57) earnings per share. Equities research analysts forecast that Establishment Labs will post -1.07 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in shares of Establishment Labs by 117.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 811,536 shares of the company’s stock valued at $59,145,000 after purchasing an additional 438,206 shares during the last quarter. Viking Global Investors LP acquired a new stake in Establishment Labs in the second quarter valued at approximately $14,669,000. Soleus Capital Management L.P. acquired a new stake in Establishment Labs in the second quarter valued at approximately $9,050,000. Summit Partners Public Asset Management LLC grew its stake in shares of Establishment Labs by 87.1% during the third quarter. Summit Partners Public Asset Management LLC now owns 430,160 shares of the company’s stock worth $17,632,000 after buying an additional 200,255 shares during the last quarter. Finally, Nantahala Capital Management LLC grew its stake in shares of Establishment Labs by 11.1% during the third quarter. Nantahala Capital Management LLC now owns 1,973,492 shares of the company’s stock worth $80,893,000 after buying an additional 197,962 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Management projected 2026 revenue of $269 million to $271 million, above the approximately $267.5 million analyst consensus. The company also said minimally invasive procedures are approaching 15% of sales, highlighting adoption of a potentially important growth area. Establishment Labs signals 2026 revenue guidance
• Positive Sentiment: Second-quarter revenue reached $67.54 million, exceeding the $65.79 million consensus estimate and increasing 31.7% from the prior-year period. The company’s loss narrowed to $0.39 per share from $0.57 a year earlier, despite missing estimates. Establishment Labs Q2 results
• Positive Sentiment: BTIG Research raised its price target from $96 to $103 and reaffirmed a Buy rating. Needham also lifted its target from $86 to $95 and assigned a Buy rating, signaling continued analyst confidence in the company’s growth outlook. Needham raises Establishment Labs price target
• Negative Sentiment: ESTA reported a quarterly loss of $0.39 per share, wider than the expected $0.34 loss. The company remains unprofitable, with a negative net margin, so investors may focus on the pace of earnings improvement and the path to profitability.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.